NEW YORK, May 5, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Puma Biotechnology, Inc. ("Puma" or the "Company") (NASDAQ: PBYI). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pbyi.
The investigation concerns whether Puma and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 4, 2017, post-market, Puma revealed that Dr. Robert Charnas, the Company's Senior Vice President, Regulatory Affairs, would be stepping down for "health reasons." Dr. Charnas's resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration's scheduled review of Puma's breast cancer drug neratinib on May 24. Following this news, Puma stock has dropped as much as $7.20 per share, or 19.7%, during intraday trading on May 5, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Puma, you can assist this investigation by visiting the firm's site: www.bgandg.com/pbyi. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-puma-biotechnology-inc-pbyi-300452411.html
SOURCE Bronstein, Gewirtz & Grossman, LLC